Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Y-700, a new kind of xanthine oxidase inhibitor in development at Yoshitomi

Aug. 14, 1998

NPY Y5 receptor antagonist suppresses feeding and reduces body weight in rodents

Aug. 13, 1998

Kissei describes AGE inhibitors for treating diabetic complications

Aug. 13, 1998

Low-dose tamoxifen reduces the risk of bone fracture in elderly women

Aug. 13, 1998

BRMAC recommends approval of Stemgen for stem cell transplant patients

Aug. 12, 1998

Draxis files for Canadian approval of oral agent for hyperparathyroidism

Aug. 12, 1998

SmithKline Beecham discovers potent and selective beta3-adrenoceptor agonists

Aug. 12, 1998

Israeli investigators describe studies with novel vitamin D analogue

Aug. 11, 1998

European Commission approves Xenical for marketing in member countries

Aug. 10, 1998

New estrogenic/antioxidant agents developed by AHP

July 31, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
In the clinic for May 26, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...